PCN150 Watch and WAIT Policy Versus Robotic Surgery for Rectal Cancer: A Cost-Utility (RECCOSTE)
Sign Up to like & getrecommendations! Published in 2020 at "Value in Health"
DOI: 10.1016/j.jval.2020.08.287
Abstract: demonstrate that the pembrolizumab Q6W scheme could generate a cost savings of V 1.2, V 2.2 and 3.0 million for 1,000 patients if compared with pembrolizumab Q3W, nivolumab and ipilimumab respectively. On average, 40% of… read more here.
Keywords: wait policy; pcn150 watch; cost; policy versus ... See more keywords